Research Article
Systemic Immune-Inflammatory Index, Tumor-Infiltrating Lymphocytes, and Clinical Outcomes in Esophageal Squamous Cell Carcinoma Receiving Concurrent Chemoradiotherapy
Table 1
Baseline clinicopathological characteristics according to SII.
| | Characteristic | Overall | SII | P-value | | Low (<1036.6) | High (≥1036.6) |
| | n | 160 | 133 | 27 | | | Gender, n (%) | | | | 0.651 | | Female | 38 (23.8%) | 33 (20.6%) | 5 (3.1%) | | | Male | 122 (76.2%) | 100 (62.5%) | 22 (13.8%) | | | Age, n (%) | | | | 1.000 | | <70 | 111 (69.4%) | 92 (57.5%) | 19 (11.9%) | | | ≥70 | 49 (30.6%) | 41 (25.6%) | 8 (5%) | | | ECOG, n (%) | | | | 1.000 | | 1 | 18 (11.2%) | 15 (9.4%) | 3 (1.9%) | | | 2 | 142 (88.8%) | 118 (73.8%) | 24 (15%) | | | Node size (cm), n (%) | | | | 0.192 | | <2.2 | 142 (88.8%) | 120 (75%) | 22 (13.8%) | | | ≥2.2 | 18 (11.2%) | 13 (8.1%) | 5 (3.1%) | | | Length (cm), n (%) | | | | 0.016 | | <8.4 | 142 (88.8%) | 122 (76.2%) | 20 (12.5%) | | | ≥8.4 | 18 (11.2%) | 11 (6.9%) | 7 (4.4%) | | | cT, n (%) | | | | 0.482 | | 1 | 2 (1.2%) | 1 (0.6%) | 1 (0.6%) | | | 2 | 13 (8.1%) | 12 (7.5%) | 1 (0.6%) | | | 3 | 72 (45%) | 59 (36.9%) | 13 (8.1%) | | | 4 | 73 (45.6%) | 61 (38.1%) | 12 (7.5%) | | | cN, n (%) | | | | 0.260 | | 0 | 40 (25%) | 37 (23.1%) | 3 (1.9%) | | | 1 | 60 (37.5%) | 48 (30%) | 12 (7.5%) | | | 2 | 45 (28.1%) | 35 (21.9%) | 10 (6.2%) | | | 3 | 15 (9.4%) | 13 (8.1%) | 2 (1.2%) | | | M, n (%) | | | | 0.081 | | No | 129 (80.6%) | 111 (69.4%) | 18 (11.2%) | | | Yes | 31 (19.4%) | 22 (13.8%) | 9 (5.6%) | | | Radiotherapy, n (%) | | | | 1.000 | | <50 | 15 (9.4%) | 13 (8.1%) | 2 (1.2%) | | | ≥50 | 145 (90.6%) | 120 (75%) | 25 (15.6%) | | | Chemotherapy cycle, n (%) | | | | 1.000 | | <2 | 85 (53.1%) | 71 (44.4%) | 14 (8.8%) | | | ≥2 | 75 (46.9%) | 62 (38.8%) | 13 (8.1%) | | | cCR, n (%) | | | | 0.205 | | No | 111 (69.4%) | 89 (55.6%) | 22 (13.8%) | | | Yes | 49 (30.6%) | 44 (27.5%) | 5 (3.1%) | | | TIL, n (%) | | | | 0.205 | | High (≥15%) | 80 (50%) | 70 (43.8%) | 10 (6.2%) | | | Low (<15%) | 80 (50%) | 63 (39.4%) | 17 (10.6%) | | | PLR, n (%) | | | | 0.005 | | <100 | 36 (22.5%) | 36 (22.5%) | 0 (0%) | | | ≥100 | 124 (77.5%) | 97 (60.6%) | 27 (16.9%) | | | NLR, n (%) | | | | < 0.001 | | <2.32 | 76 (47.5%) | 76 (47.5%) | 0 (0%) | | | ≥2.32 | 84 (52.5%) | 57 (35.6%) | 27 (16.9%) | | | LMR, n (%) | | | | <0.001 | | <2.5 | 22 (13.8%) | 7 (4.4%) | 15 (9.4%) | | | ≥2.5 | 138 (86.2%) | 126 (78.8%) | 12 (7.5%) | |
|
|
SII, systemic immune-inflammatory index; TIL, tumor-infiltrating lymphocytes; PLR, platelet-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; ECOG, Eastern Cooperative Oncology Group; cT, clinical tumor stage; cN, clinical nodes stage; M, metastasis; cCR, clinical complete response.
|
